IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

Non Small Cell Lung Cancer Clinical Trial

Official title:

Official Title: A Phase II Multicenter, Open Label, Non-randomized Study of Neoadjuvant and Adjuvant Treatment With IPH5201 and Durvalumab in Patients With Resectable, Early-stage (II to IIIA) Non-Small Cell Lung Cancer (MATISSE)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05742607
• Other study ID #: IPH5201-201
• Status: Recruiting
• Phase: Phase 2
• Start date: June 23, 2023
• Est. completion date: September 2026

Study information

• Verified date: March 2024
• Source: Innate Pharma
• Contact: Innate Pharma
• Phone: +33484903084
• Email: clinical.trials[@]innate-pharma.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is intended to assess the safety and efficacy of neoadjuvant combination of IPH5201 and durvalumab in addition to standard chemotherapy and adjuvant combination of IPH5201 and durvalumab in untreated patients with resectable, early-stage (stage II to IIIA) non-small cell lung cancer (NSCLC).

Description:

This is an open-label, single-arm multicenter study. Eligible patients will be enrolled and will receive IPH5201 + Durvalumab + standard of care chemotherapy before surgery followed by IPH5201 + Durvalumab post-surgery.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 70
• Est. completion date: September 2026
• Est. primary completion date: June 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Newly diagnosed and previously untreated patients with histologically or cytologically documented NSCLC resectable (Stage IIA to Stage IIIA) disease (according to Version 8 of IASLC Staging Manual in Thoracic Oncology 2016.

2. WHO Performance Status or Eastern Cooperative Oncology Group of 0 or 1.

3. Adequate organ and marrow function.

4. Must have a life expectancy of at least 12 weeks.

5. Body weight > 35 kg.

6. Females of childbearing potential should use an acceptable method of contraception from the time of screening throughout the total duration of the study.

7. Negative pregnancy test (serum or urine) for women of childbearing potential.

8. Provision of tumor samples (newly acquired [preferred] or archival tumor tissue [= 6 months old]) to confirm Programmed Death-Ligand 1 status, Epidermal Growth Factor Receptor, or Anaplastic Lymphoma Kinase status.

9. Provision of tumor samples appropriate for exploratory biomarker analyses.

10. Patients will be suitable for inclusion if the planned surgery to be performed will be lobectomy, sleeve resection, or bilobectomy, as determined by the attending surgeon based on the baseline findings.

11. A pre- or post-bronchodilator FEV1 of 1.0 L and DLCO > 40% postoperative predicted value.

Exclusion Criteria:

1. Participants with sensitising EGFR mutations or ALK translocations.

2. History of allogeneic organ transplantation.

3. Active or prior documented autoimmune or inflammatory disorders.

4. Uncontrolled intercurrent illness, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, active ILD, serious chronic gastrointestinal conditions associated with diarrhoea, or psychiatric illness/social situations that would limit compliance with study requirement.

5. History of any grade of venous or arterial thromboembolic events including cerebrovascular accident, transient ischemic attack, or unstable angina pectoris within 6 months prior to enrollment.

6. History of another primary malignancy.

7. Patients with small-cell lung cancer or mixed small-cell lung cancer.

8. History of active primary immunodeficiency.

9. Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis testing in line with local practice), hepatitis B (known positive HBsAg result) and HCV. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody and absence of HBsAg) are eligible. Patients positive for HCV antibody are eligible only if PCR is negative for HCV RNA.

10. Patients who have preoperative radiotherapy treatment as part of their care plan.

11. Patients who require or may require pneumonectomy, segmentectomies, or wedge resections, as assessed by their surgeon, to obtain potentially curative resection of primary tumor.

12. QTc interval = 470 ms (NOTE: If prolonged, then 2 additional ECGs should be obtained and the average QTcF interval should be used to determine eligibility).

13. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.

14. Any medical contraindication to treatment with chemotherapy as listed in the local labelling.

15. Patients with moderate or severe cardiovascular disease.

16. Any concurrent chemotherapy, investigational product, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable.

17. Receipt of live attenuated vaccine within 30 days prior to the first dose of study interventions.

18. Major surgical procedure (as defined by the Investigator) within 30 days prior to the first dose of study drugs.

19. Prior exposure to immune-mediated therapy.

20. Current or prior use of immunosuppressive medication within 14 days before the first dose of study drugs.

21. Participation in another clinical study with an investigational product administered within 30 days prior to enrolment.

22. Previous study drugs (durvalumab, IPH5201) assignment in the present study.

23. Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of study drugs administration.

24. Involvement in the planning and/or conduct of the study (applies to both company staff and/or staff at the study site).

25. Judgment by the Investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.

26. Exclusion criteria for participation in the optional (DNA) genetics research component.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non Small Cell Lung Cancer

Intervention

Drug:
• IPH5201 + durvalumab + standard chemotherapy
Patients will receive Neoadjuvant therapy with IPH5201 and durvalumab in addition to standard chemotherapy. Following surgery, patients will receive adjuvant treatment with IPH5201 and durvalumab.

Locations

Country	Name	City	State
France	Angers University Hospital Center	Angers
France	University Hospital Center Caen	Caen
France	Hospital Calmette	Lille
France	CHU de Limoges	Limoges
France	Leon Berard Center	Lyon
France	Marseille University Hospital Center - North Hospital	Marseille
France	Rennes University Hospital Center - Hospital Pontchaillou	Rennes
France	Charles Nicolle Hospital	Rouen
France	Gustave Roussy	Villejuif
Greece	Henry Dunant Hospital Center	Athens
Greece	University General Hospital "Attikon"	Athens
Greece	University General Hospital of Ioannina	Ioánnina
Greece	University General Hospital of Patras	Patras
Hungary	Koranyi National Institute of Pulmonology, 14th Department of Pulmonology	Budapest
Hungary	Veszprem County Pulmonology Institute	Farkasgyepu
Hungary	Petz Aladar University Teaching Hospital, Department of Pulmonology	Gyor
Hungary	Jasz-Nagykun-Szolnok County Hetenyi Geza Hospital-Clinic, Department of Oncology	Szolnok
Hungary	Pulmonology Institute Torokbalint	Torokbalint
Poland	University Teaching Hospital in Bialystok, 2nd Department of Lung Diseases and Tuberculosis	Bialystok
Poland	John Paul II Specialist Hospital in Krakow	Kraków
Poland	Mandziuk Slawomir - Specialist Medical Practice	Lublin
Poland	Eugenia and Janusz Zeyland Wielkopolskie Centre of Pulmonology and Thoracic Surgery	Poznan
Poland	Specialist Hospital in Prabuty Sp. z o.o. (LLC)	Prabuty
Poland	Military Institute of Medicine - National Research Institute	Warsaw
United States	University of Chicago Medical Center	Chicago	Illinois
United States	Millennium Research & Clinical Development	Houston	Texas
United States	Northwell Health Cancer Institute / Center for Novel Cancer Therapeutics	Lake Success	New York
United States	UW Carbone Cancer Center - Cancer Connect	Madison	Wisconsin
United States	St. Anthony's Hospital - BayCare Health System	Saint Petersburg	Florida
United States	H. Lee Moffitt Cancer Center & Research Institute	Tampa	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Innate Pharma

Countries where clinical trial is conducted

United States,  France,  Greece,  Hungary,  Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pathological Complete Response (pCR)	Number of patients with pathological Complete Response (pCR)	16 weeks after the first dose of study intervention.
Primary	Adverse events (AEs) and serious adverse events (SAEs)	Number of patients with adverse events (AEs) and serious adverse events (SAEs).	Until Day 90 after the last dose of study interventions.
Secondary	Event-Free Survival (EFS)	Number of patients experiencing an Event-Free Survival (EFS) event.	Up to approximately 2 years.
Secondary	Disease Free Survival (DFS)	Number of patients experiencing a Disease Free Survival (DFS) event (event from surgery onwards).	Up to approximately 2 years.
Secondary	Surgical resection	Number of participants having surgical resection.	Approximately 16 weeks after the first dose of study intervention.
Secondary	Major Pathological Response (mPR)	Number of patients with a major Pathological Response (mPR).	Approximately 16 weeks after the first dose of study intervention.
Secondary	Objective Response Rate (ORR)	Number of patients with an Objective Response Rate (ORR).	Up to approximately 4 months adjuvant.
Secondary	Overall Survival (OS)	Overall Survival (OS).	Up to approximately 2 years.
Secondary	PK of IPH5201 in combination with durvalumab +/- chemotherapy	Serum concentration (PK) of IPH5201 in combination with durvalumab +/- chemotherapy, in patients receiving neoadjuvant and adjuvant treatment.	Up to approximately 4 months adjuvant.
Secondary	Anti-study drug antibodies (ADA)	Number of patients with anti-study drug antibodies (ADA).	Up to approximately 4 months adjuvant.